P1486: TRIALS IN PROGRESS: THE THRIVE STUDIES EVALUATING THE EFFICACY, SAFETY, AND LONG-TERM TREATMENT WITH INCLACUMAB, A P-SELECTIN INHIBITOR, IN PATIENTS WITH SICKLE CELL DISEASE

• B. Andemariam,
• A. Inati,
• R. Colombatti,
• C. Minniti,
• C. Brown,
• M. Hottmann,
• S. Gray,
• C. Hoppe,
• M. Davis,
• P. Yue

Affiliations

B. Andemariam

1 New England Sickle Cell Institute, University of Connecticut Health, Farmington, United States of America

A. Inati

2 Lebanese American University, Byblos and Beirut, Nini Hospital, Tripoli, Lebanon

R. Colombatti

3 Clinic of Pediatric Hematology Oncology, Department of Woman’s and Child’s Health, Azienda Ospedale – Università di Padova, Padua, Italy

C. Minniti

4 Albert Einstein College of Medicine, Bronx

C. Brown

5 Aflac Cancer and Blood Disorder Center of Children’s Healthcare of Atlanta and Department of Pediatrics, Emory School of Medicine, Atlanta

M. Hottmann

6 Global Blood Therapeutics, South San Francisco, United States of America

S. Gray

6 Global Blood Therapeutics, South San Francisco, United States of America

C. Hoppe

6 Global Blood Therapeutics, South San Francisco, United States of America

M. Davis

6 Global Blood Therapeutics, South San Francisco, United States of America

P. Yue

6 Global Blood Therapeutics, South San Francisco, United States of America